This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Genentech, Inc.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Innovations of John Moffat in Cancer Treatment
Introduction
John Moffat is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of hyperproliferative diseases such as cancer. His innovative approach combines specific inhibitors to enhance therapeutic outcomes.
Latest Patents
John Moffat holds 1 patent for his invention titled "Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases." This patent describes the use of combinations comprising a MEK inhibitor, such as GDC-0973 or GDC-0623, along with an ERK inhibitor, such as GDC-0994. The invention is particularly useful for treating hyperproliferative disorders, including various forms of cancer.
Career Highlights
Moffat is currently employed at Genentech, Inc., a leading biotechnology company known for its focus on innovative medicines. His work at Genentech has allowed him to collaborate with other talented professionals in the field, contributing to advancements in cancer treatment.
Collaborations
Some of his notable coworkers include Marcia Belvin and Mark Merchant. Their collective expertise and collaboration have played a crucial role in the development of groundbreaking therapies.
Conclusion
John Moffat's innovative work in combining MEK and ERK inhibitors represents a significant advancement in the treatment of hyperproliferative diseases. His contributions continue to impact the field of oncology and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile